Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.
1. A method of treating diabetes in a mammalian subject having an LDL cholesterol plasma level of less than 100 mg/dL, which comprises administering to said mammalian subject:
(a) a glucagon receptor antagonist, and
(b) a cholesterol absorption inhibitor,
wherein the subject is not further being treated with a statin.
2. The method of claim 1 wherein the glucagon receptor antagonist compound and the cholesterol absorption inhibitor compound are present in a single dosage form.
3. The method of claim 2 wherein the glucagon receptor antagonist compound and the cholesterol absorption inhibitor compound are in a bilayer tablet.
4. The method of claim 1 wherein the glucagon receptor antagonist compound and the cholesterol absorption inhibitor compound are present each in a separate dosage form for simultaneous or sequential administration.
5. The method of claim 1 for treating type 2 diabetes.
6. The method of claim 1 wherein the cholesterol absorption inhibitor compound is:
or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 wherein the glucagon receptor antagonist compound is a compound selected from the following table of compounds:
or a pharmaceutically acceptable salt thereof.
8. The method of claim 1 wherein the mammalian subject is a human.
9. The method of claim 6 wherein the mammalian subject is a human.
10. The method of claim 7 wherein the mammalian subject is a human.
11. The method of claim 1 wherein the glucagon receptor antagonist compound is:
or a pharmaceutically acceptable salt thereof.
12. The method of claim 6 wherein the glucagon receptor antagonist compound is:
or a pharmaceutically acceptable salt thereof.
13. The method of claim 1 wherein the glucagon receptor antagonist compound is:
or a pharmaceutically acceptable salt thereof.
14. The method of claim 6 wherein the glucagon receptor antagonist compound is:
or a pharmaceutically acceptable salt thereof.
15. A method of reducing hyperglycemia in a mammalian subject having an LDL cholesterol plasma level of less than 100 mg/dL, which comprises administering to said mammalian subject:
(a) a glucagon receptor antagonist, and
(b) a cholesterol absorption inhibitor,
wherein the subject is not further being treated with a statin.